![[Video] The Weekly Break Out Ep. 20: Pacific policy in Singapore and the UK’s new defense plan](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Break-Out-ep-20-thumb-Play-Button.jpg?#)
J&J shares survival data on prostate cancer bispecific, furthering broad but solitary pursuit of KLK2
Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months progression-free survival in hard-to-treat prostate cancer patients.
Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months progression-free survival in hard-to-treat prostate cancer patients.
